Rhythm Pharmaceuticals (NASDAQ: RYTM) reported Q1 EPS of ($2.35), in-line with the analyst estimate of ($2.35). Revenue for the quarter came in at $25.97 million versus the consensus estimate of $27.02 million.

For earnings history and earnings-related data on Rhythm Pharmaceuticals (RYTM) click here.